Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Psilocybin in Healthy Volunteers
NCT02163707Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Jun 2014
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of psilocybin in anxiety disorder and major depressive disorder (MDD) (3 arms), sponsored by University of Wisconsin–Madison. Primary endpoint: Concentrations of psilocin following escalating doses of psilocybin at 12 months. Started Jun 2014; status: completed.
02
Drugs
psilocybin
03
Conditions
anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02163707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02163707.